Ken Langone, chairman and president of Invemed Associates and a co-founder of Home Depot, said Eli Lilly could reach $2,000 a share within three or four years. The target is 70.92% above Lilly’s Tuesday close of $1,170.14. Langone said Lilly is challenging Home Depot as his largest personal investment holding, after nearly five decades of owning Lilly shares. He attributed the outlook to Chairman and CEO David Ricks, Head of R&D Dan Skovronsky, an annual research budget of $17 billion to $18 billion and a pipeline extending beyond Mounjaro and other GLP-1 medicines. Lilly also plans a $6.5 billion Houston facility for synthetic active pharmaceutical ingredients used in oral GLP-1 drugs, while Ricks said the company captured 70% of new senior Medicare GLP-1 patients since July 1. Lilly was up 55.00% over the past year and 8.88% year to date, but down 6.79% over the past month in the latest figures.